Engineering the Medicines of TomorrowJean-Paul Kress, M.D., CEO
J.P. Morgan Healthcare Conference
January 13, 2021
2© MorphoSys
Forward-Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding tafasitamab’s ability to
treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional
interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial
performance of tafasitamab. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,”
“possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties,
which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any
historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if
MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding
risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing
and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or
future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the
further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys’ ability to obtain and maintain requisite regulatory approvals and to enroll
patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals
for tafasitamab as well as the commercial performance of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its
development programs and other risks indicated in the risk factors included in MorphoSys’ Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange
Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S.
Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and guselkumab/Tremfya®).
There is no guarantee any investigational product will be approved.
2
3© MorphoSys
MorphoSys is an Emerging Leader in Hematology-Oncology
& Autoimmune Diseases
Commercial stage biopharma company with
Monjuvi® (tafasitamab-cxix) launched in the
U.S. as first product on the market
Robust late stage clinical pipeline developed by
MorphoSys and partners
Solid cash position of approx. € 1.3 billion1 and
continuous revenue and royalty stream
600+ employees in Germany and U.S.
1) Cash Position September 30, 2020: €987.2 m (pro-forma including the
convertible bond issuance in October: ~ € 1.3 billion)
3
4© MorphoSys
Focused on Execution
1) Monjuvi (tafasitamab-cxix) is approved by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-
cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT) 2)
Cash Position September 30, 2020: €987.2 m (pro-forma including the convertible bond issuance in October: ~ € 1.3 billion)
Commercial Execution
Ensure continued successful launch of Monjuvi
Clinical Execution
Expand Monjuvi opportunity by initiating pivotal studies in 1st line
DLBCL and R/R FL
Global commercial and development collaboration with Incyte for
tafasitamab (Monjuvi®) which brought $900 million up front cash
(including equity investment)
Tafasitamab approved for r/r DLBCL in the U.S. in July 2020
Significantly strengthened balance sheet with EUR 1.3 billion2 in cash
and cash equivalents
2020 Was a Transformative Year
Focus on Execution in 2021
4
5
Products, Partnerships and Research Drive Stakeholder Value
Three drivers of value creation
© MorphoSys
Blockbuster medicine
Several additional
programs in mid and late-
stage development
First marketed product
Felzartamab in clinical
development for autoimmune
disease
Cutting-edge research
platforms and programs:
• Antibodies, T-cell engagers,
bispecifics
• Focus on oncology and
autoimmune diseases
PRODUCT REVENUEfrom MorphoSys
commercialization
ROYALTY REVENUEfrom partners
RESEARCH PLATFORMScreate opportunities to drive
long-term growth
5
6© MorphoSys
Robust Late-Stage Clinical Pipeline
Program Partner Target Disease area Ph 1 Ph 2 Ph 3 Market
Tafasitamab Incyte1) CD19
r/r DLBCL
1L DLBCL
r/r FL / MZL
Felzartamab - CD38 Autoimmune (M-PLACE)
1) Joint development globally and co-commercialization in the U.S., Incyte has exclusive commercialization rights outside the U.S. 2) For development in China, Hong Kong, Macao, Taiwan
Pipeline products are under clinical investigation and have not been proven to be safe or effective. DLBCL: diffuse large B-cell lymphoma; FL. Follicular lymphoma; r/r: relapsed/refractory
Tremfya® Janssen IL-23 p19Psoriasis
Psoriatic Arthritis
Otilimab GSK GM-CSF
Rheumatoid Arthritis (ContRAst 1-3)
Severe Pulmonary COVID-19 Related
Disease (OSCAR)
Gantenerumab Roche Amyloid-b Alzheimers Disease (Graduate 1 + 2)
FelzartamabI-Mab
Biopharma2) CD38 Multiple Myeloma
Product revenue from MorphoSys commercialization
Royalty revenue from partners
6
8© MorphoSys
Tafasitamab Received FDA Approval Mid-2020
Compelling tafasitamab profile
Potential best-in-class anti-CD19 antibody for the treatment of
certain hematological malignancies
First and only approved drug in the U.S. for 2L+ adult NTE DLBCL
in combination with lenalidomide
Global commercial partnership with Incyte
• Co-commercialization in the U.S., MorphoSys books revenues
• Incyte responsible for commercialization outside of the U.S.
Multiple studies ongoing to establish tafasitamab as potential
backbone treatment in DLBCL and to expand into other indications
8
9© MorphoSys
Addressing High Unmet Medical Need
For r/r DLBCL patients in 2L+, not eligible for
autologous stem cell transplant, MONJUVI® +
lenalidomide …
Efficacy
… is the first and only 2L+ therapy resulting in
patients having complete and durable responses
Safety & Tolerability
… has a safety & tolerability profile that supports
treatment to disease progression2
Accessibility
… can be administered in community and academic
settings
MONJUVI®, in combination with lenalidomide, is
indicated for the treatment of adult patients with
relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) not otherwise specified, including DLBCL
arising from low grade lymphoma, and who are not
eligible for autologous stem cell transplant (ASCT).1
Indication
• Best overall response rate 55% (43%-67%)
• Complete response rate 37%
• Median duration of response 21.7 (0,24) months
1This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). 2 The most serious AEs included infusion-related reactions, serious or severe myelosuppression (including neutropenia), thrombocytopenia, infections and embryo-fetal
toxicity. Permanent discontinuation of MONJUVI or lenalidomide due to an adverse reaction occurred in 25% of patients and permanent discontinuation of MONJUVI due to an adverse reaction
occurred in 15%. USPI https://www.monjuvi.com/pi/monjuvi-pi.pdf
Key efficacy data1
9
10
Continued momentum in account adoption
• >250 sites of care ordered through October
• 80% of accounts have reordered
• Growing momentum in the community setting
First sales booked in Q3
• $5M Net Sales in Q3 from dosing of first patient on
August 13 through 30 September (~7 weeks of sales)
10,000 patients in the U.S. per year eligible for
treatment with Monjuvi
© MorphoSys
Monjuvi’s® Potential in the U.S. Market
2nd Line
NTE
5,000
2nd line patients
axicabtagene ciloleucel
tisagenlecleucel
polatuzumab
selinexor
3rd Line+
NTE
5,000
3rd+line patients
Early Days of Launch Market Opportunity
10
11
Treatment with Tafa/Len Combination Results in Durable Responses
L-MIND – long-term follow-up data (≥24 months)
Salles et al., EHA 2020
Tafa+ LEN
80 77 69 64 54 37 1345Number of patients at risk
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
0 1 3 6 12 24 3618
Pro
bablity
of
overa
ll s
urv
ival
Time (months)
Censored
Median OS: 31.6 months (95% CI: 18.3-NR)
Patients with CR: >90% alive after 2 years
Time to event end point including OS are difficult to interpret in a
single arm study.
Median DoR: 34.6 months (95% CI: 26.1–34.6)
Patients with CR: >85% responding after 2 years
1.0 0.9
Pro
port
ion o
f pati
ents
in r
em
issi
on 0.8
0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
0 1 3 6 12 24 3018
Time (months)
Number of patients at risk 14 10 13 5 4 2 1 1
CR 33 30 32 29 23 22 11 Censored
47 40 45 34 27 24 12 98
PR
PR/CR
© MorphoSys11
12
• Need to improve the efficacy of R-CHOP
• Strong synergies between tafasitamab +
lenalidomide in r/r DLBCL
Combining Tafasitamab + Len / R-CHOP in 1L DLBCL
Working to address unmet need in frontline DLBCL
• 30,000 patients newly diagnosed in the U.S. per year
• High risk patients (IPI 3-5) with highest unmet
medical need,~50% of these patients do not respond to
R-CHOP or relapse
Unmet need in 1L DLBCL
Rationale supporting tafa/len combination
Screening
R-CHOP + tafasitamab + lenalidomide (75 years, stage IV, IPI 4)
After 3 cycles (CR)
THIS IS A SINGLE PATIENT RESPONSE WHICH IS PROVIDED FOR ILLUSTRATION
ONLY. THE PRODUCT IS IN DEVELOPMENT IN THIS INDICATION AND THIS
ILLUSTRATION DOES NOT GUARANTEE ALL PATIENTS WILL OBSERVE THE SAME
EFFICACY NOR HEALTH AUTHORITIES APPROVAL
© MorphoSys12
13
Pivotal phase 3 study in 1L DLBCL expected to start in H1 2021
Ambition to Improve Cure Rates in DLBCL
firstMIND study• n = 60 patients
Efficacy & Safety:
• ORR 91.1%
• Interim response assessments after 3 cycles,
both arms combined
Safety:
• No new safety signals
• No patients discontinued treatment due to AEs
Pivotal phase 3 study:
• tafa + len + R-CHOP vs. R-CHOP
• n = 900 patients
Key factors built into study:
• Addition of two synergistic drugs to R-CHOP
• Time to treatment ≤ 28 days
• High risk patients IPI 3-5
Encouraging phase 1b data in 1L DLBCL Paving the way for the start of a pivotal trial
© MorphoSys13
14
Phase 3 pivotal trial
• N = 600 patients
• tafasitamab/len + R (R2) vs R2
• Study start expected in 2021
• Aim of study: significant
prolongation of PFS
• Orphan drug designation in FL
granted by the FDA
Combining Tafasitamab + R2 in Indolent Lymphoma
Phase 3 study in r/r FL and r/r MZL expected to start in 2021
Unmet need in follicular
lymphoma
Rationale and datasupporting tafa/len combination
Development path forward in
indolent lymphoma
Tafasitamab:
• Early signs of activity observed
with tafasitamab monotherapy
Lenalidomide:
• Approved for the treatment of
FL and MZL
Building on the potential synergy
of tafasitamab and lenalidomide
1st line
~11,000
drug-treated patients1)
~1,600 deaths
per year in the U.S.2)
FL is the second most common
subtype of NHL
© MorphoSys
2nd/3rd/4th line (r/r)
~10,000
drug-treated patients1)
1) drug-treated patients in the US, source DRG, number of patients in 2021 2) source SEER database, number of patients in 20201 FL: follicular lymphoma MZL: marginal zone lymphoma
14
15
Combining Tafasitamab with New Agents
• Investigating tafasitamab in
combination with Xencor’s CD20xCD3
bispecific plamotamab
• Clinical development in r/r DLBCL, 1L
DLBCL and FL to be sponsored by Xencor
• First clinical trial to start in 2021
© MorphoSys
tafasitamab
Target: CD19
MoA: ADCC, ADCP
plamotamab
Target: CD20
MoA: T cell engagement
Exploring additional treatment options for patients with non-Hodgkin lymphomas
15
16
Tafasitamab as Backbone in DLBCL and Beyond
© MorphoSys
Establish Monjuvi-LEN as standard of care in r/r DLBCL
Develop Monjuvi as backbone in DLBCL and beyond
Expand indication into other NHL types
Incre
ase
valu
e t
hro
ugh
life
cycle
managem
ent
16
17
Multiple opportunities to address significant unmet needs in non-Hodgkin lymphomas
© MorphoSys
Broad Tafasitamab Clinical Program to Maximize Value for Patients
Study Indication Status Ph 1 Ph 2 Ph 3 Market
L-MIND r/r DLBCL FDA approved in 2L
B-MIND r/r DLBCL Ongoing
firstMIND 1L DLBCL Ongoing
frontMIND 1L DLBCL Trial initiation expected H1 2021
inMIND r/r FL / MZL Trial initiation expected H1 2021
Parsaclisib1)
combination
r/r B-cell
malignanciesTrial initiation expected 2021
CD20xCD3
combination
r/r DLBCL
1L DLBCL
r/r FL
First trial expected to start 2021Studies sponsored
by Xencor
J-MIND (Japan)r/r DLBCL
and othersOngoing
1) Parsaclisib: PI3Kd inhibitor owned by Incyte; The clinical development program does not guarantee a regulatory approval; r/r: relapsed or refractory; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma;
MZL: marginal zone lymphoma
17
19© MorphoSys
Exploring Felzartamab (MOR202) in Autoimmune Diseases
Anti-CD20,-CD19,-CD40 (L),-BAFF
Anti-FcRn,
Complement-
inhibitorsAnti-CD38 (Felza)
Earlier
B-cell
stages
Activated
B cell
Plasma-blastShort/ Long-lived
Plasma cell
Inflammation/
Organ damage
Specific targeting of autoantibody producing
plasma cells
Clinical development plan:
- PoC data from M-PLACE phase 1b/2a
study expected in H1 2021
- Ready to broaden clinical development
CD38 antibody in clinical development
First indication in development:
aMN - membranous nephropathy
- 10,000 eligible patients in the U.S. per year
- High unmet need, 30%–40% of patients progress
to end-stage renal disease (ESRD) within 5–15
years1)
Targeting CD38 – excellent way to prevent auto-Abs
First PoC data in membranous nephropathy expected in H1 2021
1) Chen et al. 2014
19
21
Designed to create combinatorial flexibility to the benefit of our patients
© MorphoSys
MOR Research Technology Platforms to Expand Pipeline
• CyCAT® = Cytotoxic Cell Activation at Tumor
• Innovative split-CD3 effector platform
OkapY™ = Innovative 2+1 TCE format
Antibody discovery platformHuCAL®, Ylanthia®, Slonomics®
Fill own pipeline
with focus on hematology-
oncology and solid cancer
Dual Targeting T-cell engagers
T-cell engagers (TCEs)
Bispecifics
Advancing proprietary
technology platforms
Antibody engineering and BiSpecific platforms OkapYTM, CyCAT®
21
23© MorphoSys
Partnered Assets Have Potential to Generate Increasing Royalty Stream
37-42 million EUR in royalties for 2020 for Tremfya, significant growth potential
Tremfya
(IL-23)
Psoriasis
Otilimab
(GM-CSF)
Rheumatoid arthritis
Gantenerumab
(amyloid-beta)
Alzheimers disease
Several programs with
different partners:
Novartis, Mereo,
Janssen, Bayer
Tremfya
(IL-23)
PsA
Felzartamab
(CD38)
Multiple myeloma
Guselkumab
(IL-23)
Crohns disease
Ulcerative colitis
MOR210
(C5aR)
Oncology
Several programs with
different partners:
Novartis, Ultragenyx, Pfizer,
BI, Anthos Therapeutics,
Shandong Fontacea
Ianalumab
(BAFF-R)
SLE, IPF
Royalties$$
Phase I Phase II Phase III Market
Milestones
23
24© MorphoSys
Expected Newsflow 2021 and Beyond
Selected programs
Tafasitamab – inMIND
Pivotal Study Start
r/r FL
Tafasitamab - frontMIND
Pivotal Study Start
1L DLBCL
Tafasitamab – Plamotamab
Start of combo studyr/r B-cell malignancies
Felzartamab - M-PLACE
Phase 1/2 data
aMN
Otilimab - OSCAR
Data from COVID-19 patients
Tafasitamab – frontMIND
Potential Regulatory Filing
1L DLBCL
Tafasitamab – inMIND
Potential Regulatory Filing
r/r FL
Otilimab – ContRAst
Phase 3 data
Rheumatoid Arthritis
Gantenerumab – GRADUATE
Phase 3 data
Alzheimer‘s Disease
Tafasitamab – B-MIND
Phase 3 data
r/r DLBCL
Tafasitamab
Expected European Approval
r/r DLBCL
Felzartamab – I-MAB
BLA for China
3L Multiple Myeloma
Tafasitamab – L-MIND
≥4 year long-term follow
up data
Tafasitamab – L-MIND
≥3 year long-term follow up data
2021 2021 continued 2022 Beyond 2022
Tafasitamab – Parsaclisib
Start of combo studyr/r B-cell malignancies
24
25© MorphoSys
In Closing. . .
Well-positioned for the future
Ongoing execution of Monjuvi launch in the U.S.
Pivotal studies start in H1 2021 to potentially
expand tafasitamab opportunity to
1L DLBCL and r/r FL
Well capitalized to execute on our growth
strategy
Robust late stage pipeline
25
The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA),
European Medicine Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and guselkumab/Tremfya®). HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®,
Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma®, LanthioPep®, ENFORCER® and Monjuvi® are trademarks of the MorphoSys Group. Tremfya® is a trademark of Janssen Biotech, Inc. XmAb® is
a trademark of Xencor, Inc.
www.morphosys.com
Thank You
Thank You
CORP-US-00049 26